These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 28883281)

  • 1. [Novel mechanism of immune evasion in cancer via structural variations of the PD-L1 gene].
    Ogawa S
    Rinsho Ketsueki; 2017; 58(8):957-965. PubMed ID: 28883281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aberrant PD-L1 expression through 3'-UTR disruption in multiple cancers.
    Kataoka K; Shiraishi Y; Takeda Y; Sakata S; Matsumoto M; Nagano S; Maeda T; Nagata Y; Kitanaka A; Mizuno S; Tanaka H; Chiba K; Ito S; Watatani Y; Kakiuchi N; Suzuki H; Yoshizato T; Yoshida K; Sanada M; Itonaga H; Imaizumi Y; Totoki Y; Munakata W; Nakamura H; Hama N; Shide K; Kubuki Y; Hidaka T; Kameda T; Masuda K; Minato N; Kashiwase K; Izutsu K; Takaori-Kondo A; Miyazaki Y; Takahashi S; Shibata T; Kawamoto H; Akatsuka Y; Shimoda K; Takeuchi K; Seya T; Miyano S; Ogawa S
    Nature; 2016 Jun; 534(7607):402-6. PubMed ID: 27281199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Regulatory Mechanisms of PD-L1 Expression and Its Role in Immune Evasion].
    Kataoka K
    Gan To Kagaku Ryoho; 2017 Nov; 44(11):967-971. PubMed ID: 29138368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Genetic Alterations Involving PD-L1/PD-L2 in Human Malignancies].
    Kataoka K
    Gan To Kagaku Ryoho; 2019 May; 46(5):841-844. PubMed ID: 31189800
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PD-L1-expressing extranodal diffuse large B-cell lymphoma, NOS with and without PD-L1 3'-UTR structural variations.
    Takahara T; Ishikawa E; Suzuki Y; Kogure Y; Sato A; Kataoka K; Nakamura S
    J Clin Exp Hematop; 2022 Jun; 62(2):106-113. PubMed ID: 35474033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells.
    Barsoum IB; Smallwood CA; Siemens DR; Graham CH
    Cancer Res; 2014 Feb; 74(3):665-74. PubMed ID: 24336068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Targeting the PD-1/PD-L1 immune checkpoint signal - a new treatment strategy for cancer].
    Hamanishi J; Konishi I
    Gan To Kagaku Ryoho; 2014 Sep; 41(9):1071-6. PubMed ID: 25248890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD-1/PD-L1 expression in human T-cell leukemia virus type 1 carriers and adult T-cell leukemia/lymphoma patients.
    Kozako T; Yoshimitsu M; Fujiwara H; Masamoto I; Horai S; White Y; Akimoto M; Suzuki S; Matsushita K; Uozumi K; Tei C; Arima N
    Leukemia; 2009 Feb; 23(2):375-82. PubMed ID: 18830259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RAS and PD-L1: A Masters' Liaison in Cancer Immune Evasion.
    Glodde N; Hölzel M
    Immunity; 2017 Dec; 47(6):1007-1009. PubMed ID: 29262340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. miR-142-5p regulates tumor cell PD-L1 expression and enhances anti-tumor immunity.
    Jia L; Xi Q; Wang H; Zhang Z; Liu H; Cheng Y; Guo X; Zhang J; Zhang Q; Zhang L; Xue Z; Li Y; Da Y; Zhao P; Zhang R
    Biochem Biophys Res Commun; 2017 Jun; 488(2):425-431. PubMed ID: 28511795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PD-L1 Is Upregulated by Simultaneous Amplification of the PD-L1 and JAK2 Genes in Non-Small Cell Lung Cancer.
    Ikeda S; Okamoto T; Okano S; Umemoto Y; Tagawa T; Morodomi Y; Kohno M; Shimamatsu S; Kitahara H; Suzuki Y; Fujishita T; Maehara Y
    J Thorac Oncol; 2016 Jan; 11(1):62-71. PubMed ID: 26762740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation of the PD-1/PD-L1 immune checkpoint confers tumor cell chemoresistance associated with increased metastasis.
    Black M; Barsoum IB; Truesdell P; Cotechini T; Macdonald-Goodfellow SK; Petroff M; Siemens DR; Koti M; Craig AW; Graham CH
    Oncotarget; 2016 Mar; 7(9):10557-67. PubMed ID: 26859684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PD-1/PD-L1 interactions contribute to functional T-cell impairment in patients who relapse with cancer after allogeneic stem cell transplantation.
    Norde WJ; Maas F; Hobo W; Korman A; Quigley M; Kester MG; Hebeda K; Falkenburg JH; Schaap N; de Witte TM; van der Voort R; Dolstra H
    Cancer Res; 2011 Aug; 71(15):5111-22. PubMed ID: 21659460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Programmed cell death ligand 1 (PD-L1) expression is not a predominant feature in Ewing sarcomas.
    Spurny C; Kailayangiri S; Jamitzky S; Altvater B; Wardelmann E; Dirksen U; Hardes J; Hartmann W; Rossig C
    Pediatr Blood Cancer; 2018 Jan; 65(1):. PubMed ID: 28868758
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients.
    Sui X; Ma J; Han W; Wang X; Fang Y; Li D; Pan H; Zhang L
    Oncotarget; 2015 Aug; 6(23):19393-404. PubMed ID: 26305724
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interferon-γ-induced PD-L1 surface expression on human oral squamous carcinoma via PKD2 signal pathway.
    Chen J; Feng Y; Lu L; Wang H; Dai L; Li Y; Zhang P
    Immunobiology; 2012 Apr; 217(4):385-93. PubMed ID: 22204817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Update on checkpoint blockade therapy for lymphoma.
    Kline J; Bishop MR
    J Immunother Cancer; 2015; 3():33. PubMed ID: 26199729
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation.
    Chen N; Fang W; Zhan J; Hong S; Tang Y; Kang S; Zhang Y; He X; Zhou T; Qin T; Huang Y; Yi X; Zhang L
    J Thorac Oncol; 2015 Jun; 10(6):910-23. PubMed ID: 25658629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The Role of PD-1/PD-L1 Signaling Pathway in Antitumor Immune Response].
    Zatloukalová P; Pjechová M; Babčanová S; Hupp TR; Vojtěšek B
    Klin Onkol; 2016; 29 Suppl 4(Suppl 4):72-77. PubMed ID: 27846724
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemopreventive agents induce programmed death-1-ligand 1 (PD-L1) surface expression in breast cancer cells and promote PD-L1-mediated T cell apoptosis.
    Zhang P; Su DM; Liang M; Fu J
    Mol Immunol; 2008 Mar; 45(5):1470-6. PubMed ID: 17920123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.